Focus: Verastem Oncology is a Massachusetts-based biotech focused on cancer stem cell-targeting therapeutics, with a commercial footprint in ovarian cancer through its lead combination therapy.
Profile data last refreshed 46m ago · AI intelligence enriched 2w ago
Best for specialists seeking hands-on roles in a focused oncology program with near-term commercial momentum, but size and transparency constraints warrant diligence on financial runway.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
First-in-class dual MEK/FAK inhibitor combination approved for low-grade serous ovarian cancer with extended LOE runway through 2042.
Help build intelligence for Verastem Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Verastem Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles